Sundar Jagannath, MD, Director of the Multiple Myeloma Program and Professor of Medicine at Mt. Sinai, is the principal investigator behind FDA accelerated approval of Xpovio (selinexor) for multiple myeloma.
Sundar Jagannath, MD, was the principal investigator of the phase 2B STORM study, the results of which led to the FDA accelerated approval of Xopvio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment.
STORM was a multicenter, single-arm, open-label study of patients with RRMM. For the study’s major efficacy outcome measure, the overall response rate (ORR) was 25.3% in the subgroup of 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. The median time to first response for these patients was 4 weeks and the median duration of response was 3.8 months.
Sundar Jagannath, MD, is Director of the Multiple Myeloma Program and Professor of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute. Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma.
Prior to joining Mount Sinai, Dr. Jagannath served as chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed in April 2010. The transplant program, with stored stem cells of more than 300 patients, and the myeloma program with ongoing clinical trials, have been integrated into The Tisch Cancer Institute.
Dr. Jagannath completed his residency in Internal Medicine at the Bronx-Lebanon Hospital Center and Harper Hospital and completed his residency in Medical Oncology at the MD Anderson Cancer Center (Univ of Texas).
Dr. Jagannath has published more than 180 peer-reviewed articles in top publications, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology and Cancer. He has presented more than 150 abstracts and authored nearly 30 book chapters.